SC/69A/IST/01

Sub-committees/working group name: IST

Preliminary Updated Gray Whale Assessment Models and Implications for the Performance of Gray Whale Strike Limit Algorithms

André E. Punt, Jonathan Scordino, John Brandon, Greg Donovan, Tomoharu Eguchi, Geof H. Givens, Aimée R. Lang, Peter Mahoney And David W. Weller



Papers submitted to the IWC are produced to advance discussions within that meeting; they may be preliminary or exploratory.

It is important that if you wish to cite this paper outside the context of an IWC meeting, you notify the author at least six weeks before it is cited to ensure that it has not been superseded or found to contain errors.

3

4

5 6

Preliminary Updated Gray Whale Assessment Models and Implications for the Performance of Gray Whale *Strike Limit Algorithms*

André E. Punt¹, Jonathan Scordino², John Brandon³, Greg Donovan⁴, Tomoharu Eguchi⁵, Geof H. Givens⁶, Aimée R. Lang⁵, Peter Mahoney⁷ and David W. Weller⁵

7 1: School of Aquatic and Fishery Sciences, University of Washington, Seattle, WA 98195-5020, USA

8 2: Makah Fisheries Management, Makah Tribe, Neah Bay, WA 98357, USA

- 9 3: ICF International, Inc. San Francisco, CA
- 10 4: IWC retired
- 11 5: NOAA Fisheries, Southwest Fisheries Science Center, La Jolla, CA
- 12 6: Givens Statistical Solutions, Santa Cruz. California
- 13 7: NOAA Fisheries, Alaska Fisheries Science Center, Seattle, CA

14 Abstract

15 The models developed and fitted during the Gray Whale Rangewide Review formed the basis for evaluating the performances of the Gray Whale SLA and the Makah Management Plan in terms of their ability to achieve 16 17 the objectives for aboriginal subsistence whaling. Elevated strandings along the eastern North Pacific 18 migration route, and declines in abundance since the completion of the Rangewide Review in 2018 are 19 indicative of a second mortality event starting in 2019. This event may suggest that the set of scenarios used 20 to evaluate the performances of the Gray Whale SLA and the Makah Management Plan may need to be revised 21 in order to take into account new information on the expected magnitude and frequency of such events. 22 Although the need for a revision remains an open question, new operating models for the eastern North 23 Pacific gray whales have been developed that include a mortality event during 2019-2022 (continuing into 24 2023) for the Northern Feeding Group and new abundance data, including for the Pacific Coast Feeding 25 Group. Trials have been conducted for stock structure hypotheses 4a/3a, 4b/3b, 4c/3c, 4e/3e, 7a/5a, and 6b, 26 with sensitivity explored to changes to assumptions related to the frequency of catastrophic events, and 27 allowance for an additional mortality event for the Pacific Coast Feeding Group. These operating models are 28 used to conduct projections under the Gray Whale SLA and the Makah Management Plan that use the new scenarios related to possible future mortality events. These models will also be useful for updating the 29 assessment of gray whales for the Scientific Committee's Status of Stocks Website project. 30

31 *Keywords*: Gray whales; Management Strategy Evaluation; Strike Limit Algorithm

32 INTRODUCTION

33 The Gray Whale Rangewide Review (GWRR) was conducted over five workshops during 2014 to

2018 (IWC, 2015, 2016, 2017, 2018, 2019a). Outcomes from the GWRR included a set of stock

- 35 structure hypotheses. The stock structure hypotheses considered whether there was an extant
- 36 Western Breeding Stock and the locations of three feeding groups within the Eastern Breeding
- 37 Stock (Western feeding Group [WFG], Northern Feeding Group [NFG], and Pacific Coast Feeding
- Group [PCFG]¹). Two of the stock structure hypotheses (3a and 5a; Table 1) formed the base case
- for many of the sensitivity tests. The population dynamics models were based on 11 sub-areas
- 40 within the north Pacific (Fig. 1; see Annex D of IWC, 2019a) and were used to evaluate the
- 41 conservation and utilization performance of the Makah Management Plan (IWC, 2019b).
- The population dynamics models developed during the GWRR were fitted to: (1) three sources of abundance data (the NOAA time series of population counts off California, the estimates of

¹ WFG: animals that feed regularly off Sakhalin Island according to photo-identification data; PCFG: animals that have been observed in two or more years during the feeding season in the PCFG area (41° N to 52° N along the coast of North America, excluding Puget Sound) according to photo-identification data; NFG: animals found in other areas (and for which there is relatively little information including photo-ID) (IWC, 2019a).

abundance for the PCFG, and the estimates for the WFG / Western Breeding Stock); (2) the
proportions of stocks / feeding groups in some of the sub-areas based on photo-identification data,
and; (3) data on survival rates for the PCFG and data on bycatch by sub-area. The models also
involved assumptions about the immigration rate from the NFG to the PCFG and the proportion
of animals killed due to bycatch in fisheries that are included in bycatch reports (Annex D of IWC,
2019a).

50 Subsequent to the GWRR, new information pertaining to stock structure was reviewed by the 51 Scientific Committee, which determined that hypotheses 4a and 7a should be elevated to high 52 priority for inclusion in the modeling, while hypotheses 3a and 5a should be considered medium 53 priority (IWC 2021, 2022). Of note, however, is that hypotheses 3a and 4a and hypotheses 5a and 54 7a are functionally equivalent for modelling purposes and thus no new model runs were required 55 to evaluate them.

56 New data are now available on removals (due to aboriginal takes) and abundance (ENP gray whales from NOAA California counts and estimates of abundance for the PCFG). In 2019, the 57 number of gray whales stranded along the coast of North America increased markedly and led to 58 the declaration of an Unusual Mortality Event in the US² (Fauquier et al., 2022). The NOAA 59 population counts off California during the winter of 2019/2020 and 2021/2022 indicated that the 60 abundance had declined by ~40% since 2015 and 2016 (Fig. 2a, Stewart and Weller, 2021; Eguchi 61 et al., 2022). The abundance data for the PCFG are also suggestive of a reduction in abundance 62 63 starting in 2016 (Fig. 2b; Harris et al. 2022) coincident with a marine heat wave (Peterson et al. 2017) that may have affected body condition of PCFG whales and the availability of their prey 64 (Torres et al., 2022). The original (Implementation) trials used to evaluate the Grav Whale SLA 65 were based on a single-stock operating model, and considered trials with (a) three mortality events 66 between years 1-75 (with at least two during years 1-50) in which 20% of animals die, and (b) a 67 mortality event during 1999/2000 in which 40% of animals die (trials GE41-50 in IWC, 2005), 68 while those used to evaluate the Makah Management Plan were based on the multi-stock 69 Rangewide operating model, and explored one catastrophic event in years 1-50 and another in year 70 51-99 of the projection period, with the magnitude equal to that of the mortality rate in 1999 and 71 2000 (approximately 13% per year). The new abundance data may suggest that the scenarios 72 considered in previous evaluations of SLAs and the Makah Management Plan may need to be 73 expanded. 74

This paper documents how the specifications of the population models, on which the operating 75 76 models for gray whales are based, can be modified to include additional mortality events. It reports on the results of conditioning a subset of the trials developed during the GWRR but using the 77 modified specifications and the new NOAA California count data and estimates of abundance for 78 the PCFG. The historical period covered by the operating models is extended from 1930 – 2016 79 (GWRR) to 1930 - 2022. The trials are then used to calculate performance statistics for the *Gray* 80 Whale SLA and the Makah Management Plan under the assumption that the latter is first applied 81 82 in 2023. The paper concludes with some steps to be conducted if a special *Implementation Review* were to be declared by the Scientific Committee (see Appendix 9 of IWC, 2019b for the details of 83 why a special Implementation Review might be declared), given that the updates to the operating 84 85 models are provisional because not all of the data sources used for conditioning were updated.

² Updated reporting on this event is available at <u>https://www.fisheries.noaa.gov/national/marine-life-distress/2019-2023-gray-whale-unusual-mortality-event-along-west-coast-and</u>

86 METHODS

87 New and revised data

88 Figure 2 compares the most recent ENP population counts from the NOAA California and PCFG

- abundance estimates with those used in the final GWRR analyses. The GWRR assumed that the
- 90 NOAA California counts were independent while the analyses of this paper include a variance-
- 91 covariance matrix for log (abundances) for 2006-2021. Table 2 lists the aboriginal catches for
- 92 2010+ used in the trials on which the GWRR was based and those used in the current analyses.
- No new abundance estimates for the Western Breeding Stock and WFG were available at the
 time of writing nor was new information on mixing proportions or bycatch available.

95 Updated operating model specifications

- 96 The specifications for the trials are provided in IWC (2019b). The two changes to the model
- 97 specifications (apart from extending the modelled period from 1930 to 2016 to 1930 to 2022) were
- to (a) estimate the annual survival rate for the NFG in 1998 and 1999 for the first UME (it was set
- 99 to 0.87 in the GWRR trials; based on that estimated in the trials for the original *Implementation*),
- 100 (b) estimate an annual survival rate for the NFG for 2018 2021 for the most recent UME, and (c)
- 101 estimate an reduction in productivity (model a lower annual survival rate) for the PCFG in 2016^3
- 102 (a subset of trials).

103 *Trials considered and exploration of management performance*

- Table 3 lists the trials considered in this paper. These trials focus on sensitivity to the stock structure hypothesis and how future catastrophic events are modelled. The trials used for GWRR also considered scenarios related to the ratio of actual to reported bycatch, the magnitude of immigration from the NFG to the PCFG in 1999 and 2000, the values for MSYR₁₊, modifications to the base-case stock structure hypotheses given lack of data on whether mixing occurs in some sub-areas, struck and lost rates, and false negative rates for determining if a whale captured in the Makah Usual and Accustomed Area is a PCFG whale.
- The *Gray Whale SLA* is documented in IWC (2005) while the Makah Management Plan is documented in Appendix A of this document. The evaluations of management performance were based on 100-year projections where California counts are collected every five years while PCFG estimates of abundance are assumed to be available annually, with a lag of two years (i.e., the application of the Makah Management Plan in 2023 would be based on data until 2021). The first year for application of the Makah Management Plan is 2023 for the analyses of this paper.
- 117 Trials with catastrophic events are considered for the two base-case trials (3a0 and 5a0) and 118 the variants thereof that allow for a reduction in the growth rate for the PCFG in 2016 (3a2 and 119 5a2). These trials are justified and defined as follows.
- a. Two periods with UMEs have occurred during the 50ish years with survey estimates of
 abundance for the ENP population. This is captured in the trials by having two periods
 with catastrophic events that impact the NFG occurring during each of the first and second
 50-year periods of the projection (four events in total). The first and third future UMEs
- are two years long (mimicking the 1999-2000 event) and the second and fourth UMEs are

³ Torres et al. (2022) suggests that PCFG whales had poorer condition during the marine heat wave (although they do not show any data during the event). With poorer condition, more may have perished, but they could have also emigrated to other feeding areas such as Kodiak Island or up to the Arctic and not been available for PCFG abundance estimates.

four years long (mimicking the recent event). The first future UME occurs during one of 125 years 9-13 for two years and the second event occurs 20 years later for four years, with 126 the third event occurring during one of years 59-63 for two years and the fourth event 127 twenty years after the third event for four years. The magnitude of the first and third future 128 UMEs matches that for the 1999-2000 UME as estimated when conditioning the replicate 129 for the trial and the magnitude of the second and fourth UMEs matches that for 2019-2022 130 UME as estimated when conditioning the replicate. This formulation implies that the sizes 131 of future catastrophic events differ among replicates (trials 3a0, 3a2, 5a0, 5a2). 132 b. One (potential) event has occurred for the PCFG over 20ish years. This is captured in 133 variants of trials 3a2 and 5a2 by having one catastrophic event that impacts the PCFG 134 randomly in each 20-year block within the projection period (i.e., one event in each of 135 years 0-19, 20-39, etc.), with the size of the event equal to the size of the reduction in 136 productivity estimated for 2016 for the associated replicate (trials 3a2 and 5a2 only). 137 c. There are impacts on both the NFG and PCFG (combining the effects of "a" and "b") 138 (trials 3a2 and 5a2 only). 139 The performance statistics used to evaluate the *Gray Whale SLA* and the Makah Management 140 Plan are a subset (1+-based) of the quantitative statistics selected by IWC (2019a), with additional 141 performance statistics to summarize the likelihood of catching western gray whales and the 142 performance of the Makah Management Plan in terms of strikes and landed whales. For each 143 144 statistic, the median, lower 5th and upper 5th percentiles are shown. • D1. 1+ Final 1+ depletion, P_T/K by breeding stock / feeding group. 145 • D2. Lowest depletion: $\min(P_t/K)$: t=0, 1, ..., T. 146 • D8. Rescaled final 1+ depletion, $P_{\rm T}/P_0$ by breeding stock / feeding group, where P_0 is 147 the number of 1+ animals had there been no future Makah hunts. 148 • D10. Relative increase. The ratio of the 1+ population size after 10 and 100 years to 149 that at the start of the projection period by breeding stock / feeding group. 150 Need satisfaction. The proportion of the total number of requested strikes that were 151 • taken over the first 10 years (Makah hunt) and the entire 100-year period (Russian and 152 Makah hunts). 153 154 • Total number of western gray whales taken during hunts over the 100-year projection period. 155 • Total number of landed whales in the Makah Usual and Accustomed area over the 100-156 year projection period. 157 • Total number of struck whales in the Makah Usual and Accustomed Area over the 100-158 year projection period. 159 **RESULTS** 160 Conditioning results 161

Not including additional mortality during 2019-2022 led to very poor fits to the NOAA ENP population counts from California (results not shown). Figures 3 and 4 show the fits to the abundance estimates and Figures 5 and 6 the fits to the other data sources. Figure 7 shows the distribution of the estimates of some of the key parameters of the population dynamics model for trials 3a0 and 3a2 and Figure 8 shows the model-predicted bycatch by sub-area over time for trial 3a0 (results are shown for a subset of the trials for the latter two diagnostics as they are visually identical among trials).

All of the trials mimic the NOAA ENP population counts from California well (Figures 3 and 169 4); although there is some evidence that if the model does not allow for a decline in productivity 170 in 2016, it predicts higher PCFG abundance than recent estimates indicate. In contrast, allowing 171 172 for a mortality event in 2016 (trials 3a2 and 5a2) leads to better fits to these data (as expected). The fits to the estimates for the western part of the range are poorer but this is consistent with the 173 trials conducted for the GWRR. The trials fit the mixing proportions, the immigration rate and the 174 bycatch data well, with the fit to the survival rates for the PCFG less well (but this was also the 175 case for the GWRR). 176

177 The trials infer that the mortality events of ENP whales during 1998-1999 and 2019-2020+

were substantial (15% and 12% annual reductions in abundance on average but note that the 2^{nd} mortality event has been longer so its effect is larger). The effect of the 2016 reduction in

- 180 productivity on the PCFG is estimated to be about 10% in a single year.
- 181 *Projection results*

182 Figure 9 shows four time-trajectories of 1+ abundance by breeding stock/feeding group for trials

- 183 3a0 and 3a2 and the variants thereof that include future mortality event (3a1, 3a3 and 3a4). The total aboriginal actab is assumed to be bounded by the constant need envelope.
- total aboriginal catch is assumed to be bounded by the constant need envelope.
- Table 4, 5 and 6 show the values of the performance statistics for the trials with no future mortality events, those for trials 3a0 and 3a2 and variants thereof that include future mortality
- events, and those for trials 5a0 and 5a2 and variants thereof that include future mortality events.
- 188 <u>No future morality events</u>
- 189 All breeding stocks / feeding groups are larger than 80% of their (current) carrying capacities after
- 190 100 years in the absence of future mortality events with high (>95%) probability (trials 3a0, 3b0,
- 191 3c0, 3e0, 5a0, and 6b0) (Table 4). The NFG is about 10% larger than its current size after 100
- 192 years for these trials while the PCFG is 93% of its current size or larger. Need satisfaction is high
- 193 for the ENP gray whales (essentially 100% need satisfaction according to the N9 statistic) while
- need satisfaction for the Makah hunt is notably lower, with landings ranging between an average
- 195 of 0.8 to 1.3 animals annually and strikes between 1.3 and 2.0.
- 196 <u>With future mortality events</u>
- As expected, the NFG and PCFG are at smaller fractions of their carrying capacities after 100 years when future mortality events are assumed (Tables 5 and 6). The final depletion remains above 0.6 with 0.95 probability (D1 statistic) even though there are cases in which population size drops below the current population size (D2 statistic). For these trials, however, the primary driver
- of population decline is future mortality events and not aboriginal catches, suggesting the value of
- statistics such as D8, which indicate that PCFG removals are not the main cause for the lower final
- 203 population size. Need satisfaction for the ENP gray whales as a whole remains high, but the
- numbers of strikes and landings under the Makah Management Plan are lower, particularly for the
- scenarios that involve future mortality events in both the NFG and PCFG.
- 206

207 **DISCUSSION**

- 208 The results, while preliminary, provisional and incomplete, suggest that the performances of the
- 209 Gray Whale SLA and the Makah Management Plan are likely robust to the recent UMEs and future
- 210 mortality events.
- 211 The analyses provided in this paper are preliminary because several data sources used during
- the GWRR have yet to be updated, and are primarily based on recent updates in NOAA California

counts, estimates of abundance for the PCFG, and aboriginal catches. In particular, the mixing
rates derived from photo-id data have not been updated, nor have the estimates of survival rate for

- the PCFG, the estimate of abundance for the western part of the range, and bycatch and ship strikes
- since 2015. All of these data sets need to be updated prior to final conclusions being drawn.

The projections are based on a subset of the model configurations used to test the *Gray Whale SLA* and the Makah Management Plan, with a focus on stock structure uncertainty and the possibility of future mortality events. The full set of sensitivity tests explore the effects of additional sources of uncertainty, in particular, how observed strandings pertain to actual numbers of animals dying due to bycatch and ship strikes. Given a focus on future mortality events, there would be value considering additional performance statistics based on variants of D8 to better understand the relative effects of mortality events and aboriginal catches on future time-trajectories

- 224 of population size.
- Finally, while this document was written primarily to evaluate the impact of the performances
- of the Gray Whale SLA and the Makah Management Plan, its results are also relevant to the Status
- of Stocks project, given the current agreed assessment of north Pacific gray whales was conducted
- before the most recent UME for the ENP gray whales.

229 **REFERENCES**

- Eguchi, T., Lang, A.R. and Weller, D.W. 2022. Abundance and migratory phenology of eastern North Pacific gray
 whales 2021/2022. U.S. Department of Commerce, NOAA Technical Memorandum NMFS-SWFSC-668.
- Fauquier D., Raverty S., Cottrell P., Macconnachie S., Viloria-Gómora L., Martínez-Aguilar S., Swartz S., Huggins
 J.L., Halaska B., Flannery M., Danil K., Savage K., and Garner M. 2022. Update on the eastern North Pacific
 gray whale (*Eschrichtius robustus*) 2019-2022 unusual mortality event. Paper SC/68D/CMP/14 Presented to the
 Scientific Committee of the International Whaling Commission.
- Harris, J., Calambokidis, J., Perez, A. and Mahoney, P.J. 2022. Recent trends in the abundance of seasonal gray whales
 (*Eschrichtius robustus*) in teh Pacific Northwest, 1996-2020. AFSC Processed Rep. 2022-05, 22 p. Alaska Fish.
 Sci. Cent., NOAA, Natl. Mar. Fish. Serv., 7600 Sand Point Way NE, Seattle WA 98115.
- IWC. 2005. Report of the Standing Working Group (SWG) on the Development of an Aboriginal Subsistence Whaling
 Management Procedure (AWMP). J. Cetacean Res. Manage 7 (Suppl.) 115-87.
- IWC. 2015. Report of the Workshop on the Rangewide Review of the Population Structure and Status of North Pacific
 Gray Whales. J. Cetacean Res. Manage 16 (Suppl.) 489-528.
- IWC. 2016. Report of the Second Workshop on the Rangewide Review of the Population Structure and Status of
 North Pacific Gray Whales. J. Cetacean Res. Manage 17 (Suppl.) 567-81.
- IWC. 2017. Report of the Third Workshop on the Rangewide Review of the Population Structure and Status of North
 Pacific Gray Whales. J. Cetacean Res. Manage 18 (Suppl.) 643-71.
- IWC. 2018. Report of the Fourth Rangewide Workshop on the Status of North Pacific Gray Whales. J. Cetacean Res.
 Manage 19 (Suppl.) 521-36.
- IWC. 2019a. Report of the Fifth Rangewide Workshop on the Status of North Pacific Gray Whales. J. Cetacean Res.
 Manage 20 (Suppl.) 569-99.
- IWC. 2019b. Report of the Standing Working Group on Aboriginal Subsistence Whaling Management Procedures.
 Annex E to report of the Scientific Committee. J. Cetacean Res. Manage 20 (Suppl.) 120-82.
- IWC. 2021. Summary of gray whale stock structure hypotheses. Annex F to the Report of the Scientific Committee.
 J. Cetacean Res. Manage 22 (Suppl.) 166-174.
- IWC. 2022. Summary of gray whale stock structure hypotheses. Annex G to the Report of the Scientific Committee.
 J. Cetacean Res. Manage 23 (Suppl.) 00-00.
- Peterson, W.T., Fisher, J.L., Strub, P.T., Du, X., Risien, C., Peterson, J., et al. 2017. The pelagic ecosystem in the northern California Current off Oregon during the 2014–2016 warm anomalies within the context of the past 20 Years. J. Geophy. Res.: Oceans. 122, 7267–7290.
- Stewart, J.D. and Weller, D.W. 2021. Abundance of eastern North Pacific gray whales 2019/2020. U.S. Department
 of Commerce, NOAA Technical Memorandum NMFS-SWFSC-639.
- Torres L.G., Bird C.N., Rodríguez-González F., Christiansen F., Bejder L., Lemos L., Urban R.J., Swartz S.,
 Willoughby A., Hewitt J. and Bierlich K. 2022. Range-wide comparison of gray whale body condition reveals

- contrasting sub-population health characteristics and vulnerability to environmental change. *Front. Mar. Sci.* 9: 86758. 264 265 266 267

Table 1. Summary of the stock structure hypotheses (IWC, 2021). Note that hypotheses 4a (and its variants) and 7a

are functionally equivalent to hypotheses 3a (and variants) and 5a, respectively, differing only in that 3a and 5a consider the WFG to be part of the Eastern Breeding Stock (EBS).

271

Stock structure hypothesis	Key features
4a*	Whales exhibit matrilineal fidelity to feeding grounds. Two breeding stocks exist: an eastern breeding stock (EBS) that includes the Northern Feeding Group (NFG) and Pacific Coast Feeding Group (PCFG) and a second breeding stock that includes Western Feeding Group (WFG) wholes that mate
	largely with each other while migrating to Mexico (M). Although a third breeding stock (the WBS)
	may once have existed, the WBS is assumed to have been extirpated. Southern Kamchatka and
	Northern Kuril Islands (SKNK) is used by both the WFG whales and the NFG whales.
4b	Identical to hypothesis 4a, except that NFG whales do not feed off SKNK. In addition, a western
	breeding stock exists that overwinters in Vietnam-South China Sea (VSC) and feeds in the Okhotsk Sea
	(OS) (but not Sakhalin Island (SI)) and SKNK. Thus, SKNK is used by both the WFG whales and the
	whales of the Western breeding stock.
4c	Identical to 4a, except that on occasion whales migrating between the Sakhalin feeding region and
	Mexico travel through the Northern Bering and Chukchi Sea (BSCS) sub-area
4e	Identical to hypothesis 4a, except that the western breeding stock is extant and feeds off both coasts of
	Japan and Korea and in the northern Okhotsk Sea west of the Kamchatka Peninsula but not off Sakhalin Island (i.e., all of the whales feeding off Sakhalin overwinter in the eastern North Pacific)
7a*	Three breeding stocks exist: EBS and WBS and an unnamed stock of WEG whales that largely breed
7 a	with each other while on migration to M. The EBS includes two feeding groups: PCFG and NFG. The
	WBS whales feed in Sakhalin Island (SI). OS, and SKNK and then migrate to VSC to overwinter.
	SKNK is used by the WFG, the NFG, and the feeding whales that are part of the WBS.
6b	This hypothesis assumes that the WFG does not exist, but that whales feeding in the SI sub-area
	represent an extant western breeding stock that utilizes two wintering grounds (VSC and M). This
	hypothesis differs from hypothesis 7a, in that 1) all removals off China and Japan are assumed to be
	western breeding stock animals, and 2) the abundance estimates for Sakhalin are assumed to relate only
	to the western breeding stock.

* Base-case model

273

274

Table 2. Aboriginal catches for 2010+ from the GWRR and the analyses of this paper. The split of the catches to sex

- is assumed to be 45:55 male:female for 2017 onwards.
- 277

Year	GWRR	This paper	Year	GWRR	This paper
2010	118	118	2017	N/A	120
2011	130	130	2018	N/A	108
2012	143	143	2019	N/A	137
2013	127	127	2020	N/A	136
2014	124	124	2021	N/A	127
2015	125	125	2022	N/A	127*
2016	120	120			

* Assumed.

- 282 283 Table 3. The trials. All trials assumed $MSYR_{1+}=0.045$, have an immigration rate of 2 per year into the PCFG, assume that a pulse of 20 whales per year moved from the NFG to the PCFG in 1999 and 2000, and assume that actual bycatch is four times the observed number.

Trial	Stock hypothesis	Catastrophic events
3a0	4a/3a	None
3b0	4b/3b	None
3c0	4c/3c	None
3e0	4e/3e	None
5a0	7a/5a	None
6a0	6b	None
3a2	4a/3a	None; but a mortality event is estimated for the PCFG in 2016
5a2	7a/5a	None; but a mortality event is estimated for the PCFG in 2016
3a1	4a/3a	As for 3a0, except with future NFG events
3a3	4a/3a	As for 3a2, except with future PCFG events
3a4	4a/3a	As for 3a2, except with future NFG and PCFG events
5a1	7a/5a	As for 5a0, except with future NFG events
5a3	7a/5a	As for 5a2, except with future PCFG events
5a4	7a/5a	As for 5a2, except with future NFG and PCFG events

287	Table 4. Performance statistics for the trials in which there are no future mortality events.
-----	---

bliclicity bliclity b	288																														
NB NF NF<			D1 (1+) (10)			D1 (1+)) (100)			D2 (1+)	(100)			D8 (1+)	(100)			D10 (1-	+) (10)			D10 (1	+) (100)		N9(N)	N(P)	N9(P)	WG	UL	US
Prior Prio		WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	100	100	10	100	100	100
54 1.0 0.99 0.8 1.00 0.90 0.91 <th< td=""><td>Trial 3a</td><td>)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Trial 3a)																													
Net 100 0.99 0.91 0.87 0.07 0.93 0.78 0.97 0.98 0.91 0.90 0.91 0.10 0.92 0.92 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.94 0.90 0.90 0.91 0.90 <th< td=""><td>5%</td><td>1.00</td><td>0.99</td><td>0.90</td><td>0.83</td><td>1.00</td><td>0.90</td><td>0.69</td><td>0.75</td><td>0.98</td><td>0.75</td><td>0.50</td><td>0.75</td><td>1.00</td><td>1.00</td><td>0.96</td><td>0.96</td><td>1.00</td><td>1.13</td><td>1.12</td><td>0.93</td><td>1.00</td><td>1.19</td><td>1.17</td><td>1.01</td><td>1.00</td><td>0.54</td><td>0.36</td><td>0</td><td>86</td><td>134</td></th<>	5%	1.00	0.99	0.90	0.83	1.00	0.90	0.69	0.75	0.98	0.75	0.50	0.75	1.00	1.00	0.96	0.96	1.00	1.13	1.12	0.93	1.00	1.19	1.17	1.01	1.00	0.54	0.36	0	86	134
9/8 100 0.90 0.91 0.80 0.90 0.80 <	Med	1.00	0.99	0.91	0.87	1.00	0.93	0.78	0.79	0.98	0.81	0.60	0.79	1.00	1.00	0.98	0.97	1.01	1.14	1.18	0.95	1.02	1.22	1.39	1.04	1.00	0.68	0.80	1	105	171
Transport 5% 0% 0.90 0.80 0.81 0.92 0.9	95%	1.00	0.99	0.91	0.89	1.00	0.94	0.86	0.83	1.00	0.83	0.73	0.83	1.01	1.10	1.21	1.06	1.01	1.19	1.21	0.98	1.02	1.31	1.60	1.07	1.00	0.82	0.88	3	127	204
58 0.90 0.90 0.82 0.92 0.95 0.69 0.75 0.85 0.81 0.90 0.90 0.90 0.80 0.90 0.80 0.90 0.80 0.80 0.90 0.90 0.90 0.80 0.80 0.90 0.90 0.90 0.90 0.80 0.90 0	Trial 3b)																													
Med 9.98 0.99 0.90 0.89 0.98 0.97 0.60 0.12 1.18 0.95 1.07 1.04 1.00 0.88 0.90 1.17 9.96 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.91 0.90 0.90 0.90 0.91 0.91 0.90 0.90 0.91 0.90 <	5%	0.96	0.99	0.90	0.83	0.92	0.95	0.69	0.75	0.85	0.83	0.50	0.75	0.98	1.00	0.96	0.96	1.01	1.09	1.12	0.93	0.98	1.13	1.16	1.01	1.00	0.56	0.36	0	83	140
95% 0.99 1.00 0.91 0.89 0.69 0.89 0.10 1.11 0.89 0.80 0.89 1.00 0.88 0.90 1.13 0.89 0.90 1.19 1.58 1.07 1.00 0.82 0.88 3 1.26 2.04 Trial 3-0 1.11 0.88 0.90 0.83 0.90 0.83 0.90 0.60 0.90 0.90 0.90 0.90 0.90 0.91 0.91 0.91 0.93 0.91 <	Med	0.98	0.99	0.90	0.86	0.98	0.95	0.78	0.80	0.93	0.85	0.61	0.79	1.00	1.00	0.98	0.97	1.06	1.12	1.18	0.95	1.05	1.17	1.37	1.04	1.00	0.68	0.80	1	105	171
Trial Jetal Trial Jetal <t< td=""><td>95%</td><td>0.99</td><td>1.00</td><td>0.91</td><td>0.89</td><td>1.02</td><td>0.96</td><td>0.87</td><td>0.83</td><td>0.97</td><td>0.88</td><td>0.74</td><td>0.83</td><td>1.03</td><td>1.08</td><td>1.20</td><td>1.06</td><td>1.07</td><td>1.14</td><td>1.21</td><td>0.98</td><td>1.09</td><td>1.19</td><td>1.58</td><td>1.07</td><td>1.00</td><td>0.82</td><td>0.88</td><td>3</td><td>126</td><td>204</td></t<>	95%	0.99	1.00	0.91	0.89	1.02	0.96	0.87	0.83	0.97	0.88	0.74	0.83	1.03	1.08	1.20	1.06	1.07	1.14	1.21	0.98	1.09	1.19	1.58	1.07	1.00	0.82	0.88	3	126	204
5% 1.00 0.88 0.90 0.83 1.00 0.70 0.68 0.75 0.98 0.75 1.00 0.96 0.96 1.00 1.10 0.12 1.15 1.01 1.00 0.52 0.36 0 8.3 1.11 Med 1.00 0.89 0.90 0.91 0.89 0.90 0.91 0.89 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.93 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.90 0.91 0.91 0.90 0.91 0.9	Trial 3c)																													
Med 1.00 0.89 0.91 0.86 1.00 0.77 0.78 0.80 0.61 0.79 1.00 0.98 0.90 0.10 1.22 1.18 0.95 1.12 1.23 1.23 1.21 0.93 1.02 1.47 1.23 1.00 0.67 0.80 1 105 168 95% 0.09 0.91 0.89 1.00 0.83 0.87 0.83 1.00 0.75 0.83 1.01 1.25 1.18 1.06 1.01 1.35 1.16 1.01 1.00 0.82 0.88 3 126 2.44 Trial 3-0 0.99 0.99 0.93 0.43 1.14 0.84 0.68 0.75 0.95 0.81 1.00 0.96 0.96 0.88 1.20 1.12 0.93 0.64 1.43 1.64 1.61 1.00 0.65 0.68 1.61 0.99 0.99 0.90 0.87 1.08 0.96 0.96 0.96 0.91 1.31 1.21 0.93 0.64 1.43 1.04 1.00	5%	1.00	0.88	0.90	0.83	1.00	0.70	0.68	0.75	0.98	0.51	0.49	0.75	1.00	0.96	0.96	0.96	1.00	1.19	1.11	0.93	1.00	1.28	1.15	1.01	1.00	0.52	0.36	0	83	131
95% 1.00 0.90 0.91 0.89 1.00 0.83 0.87 0.83 1.00 0.75 0.83 1.01 1.25 1.18 1.06 1.01 1.35 1.21 0.98 1.02 1.74 1.62 1.07 1.00 0.82 0.88 3 126 244 Trial 3cb Trial 3cb Trial 3cb Trial 3cb 0.95 0.90 0.83 0.14 0.83 0.40 0.85 0.64 0.88 1.00 0.96 0.88 1.20 1.12 0.93 0.64 1.32 1.16 1.01 1.00 0.53 0.36 0 8.3 1.00 0.96 0.96 0.88 1.20 1.12 0.93 0.64 1.32 1.16 1.01 1.00 0.53 0.36 0 8.3 1.00 0.96 0.96 0.93 1.26 1.18 0.95 0.64 1.44 1.39 1.04 1.00 0.67 0.83 1.05 1.63 1.44 1.39 1.04 1.00 0.63 1.25 1.16 1.13 1.01 1.00	Med	1.00	0.89	0.91	0.86	1.00	0.77	0.78	0.80	0.98	0.60	0.61	0.79	1.00	0.98	0.98	0.97	1.01	1.28	1.18	0.95	1.02	1.49	1.37	1.03	1.00	0.67	0.80	1	105	168
Strill 3cl Strill 3cl <td>95%</td> <td>1.00</td> <td>0.90</td> <td>0.91</td> <td>0.89</td> <td>1.00</td> <td>0.83</td> <td>0.87</td> <td>0.83</td> <td>1.00</td> <td>0.70</td> <td>0.75</td> <td>0.83</td> <td>1.01</td> <td>1.25</td> <td>1.18</td> <td>1.06</td> <td>1.01</td> <td>1.35</td> <td>1.21</td> <td>0.98</td> <td>1.02</td> <td>1.74</td> <td>1.62</td> <td>1.07</td> <td>1.00</td> <td>0.82</td> <td>0.88</td> <td>3</td> <td>126</td> <td>204</td>	95%	1.00	0.90	0.91	0.89	1.00	0.83	0.87	0.83	1.00	0.70	0.75	0.83	1.01	1.25	1.18	1.06	1.01	1.35	1.21	0.98	1.02	1.74	1.62	1.07	1.00	0.82	0.88	3	126	204
5% 0.95 0.99 0.90 0.83 1.14 0.84 0.68 0.75 0.95 0.64 0.49 0.75 0.81 1.00 0.96 0.96 0.88 1.20 1.12 0.93 0.64 1.32 1.16 1.01 1.00 0.53 0.36 0 83 133 Med 0.99 0.99 0.90 0.87 1.18 0.87 0.78 0.99 0.69 0.60 0.79 0.88 1.00 0.98 0.93 1.26 1.18 0.95 0.78 1.44 1.39 1.04 1.00 0.67 0.80 1 105 168 95% 1.00 0.99 0.91 0.89 1.33 0.91 0.87 0.83 1.00 0.96 0.96 0.13 1.21 0.98 0.83 1.55 1.63 1.00 0.82 0.83 1.25 0.40 0.83 0.56 0.60 0.96 0.96 0.96 0.17 1.12 0.98 0.83 1.55 1.63 1.01 1.00 0.36 0.86 0.83	Trial 3e)																													
Med 0.99 0.99 0.90 0.87 1.18 0.87 0.78 0.79 0.99 0.98 1.00 0.98 0.98 0.93 1.26 1.18 0.95 0.78 1.44 1.39 1.04 1.00 0.67 0.80 1 105 168 95% 1.00 0.99 0.91 0.89 1.33 0.91 0.87 0.83 1.00 0.75 0.83 1.00 1.23 1.19 1.06 0.94 1.31 1.21 0.98 0.83 1.65 1.63 1.07 1.00 0.82 0.88 3 125 2.04 Trial 5a0 . . 0.98 0.91 0.87 0.88 0.67 0.49 0.76 0.84 1.00 0.96 0.96 1.17 1.12 0.93 0.81 1.35 1.15 1.01 1.00 0.52 0.36 0 82 1.30 Med 1.00 0.98 0.91 0.98 0.91 0.96 0.96 0.96 0.17 1.12 0.93 0.81 1.51	5%	0.95	0.99	0.90	0.83	1.14	0.84	0.68	0.75	0.95	0.64	0.49	0.75	0.81	1.00	0.96	0.96	0.88	1.20	1.12	0.93	0.64	1.32	1.16	1.01	1.00	0.53	0.36	0	83	133
95% 1.00 0.99 0.91 0.89 1.33 0.91 0.87 0.83 1.00 0.12 1.19 1.06 0.94 1.31 1.21 0.98 0.83 1.07 1.00 0.82 0.88 3 125 2.04 Trial 5a0 5% 1.00 0.98 0.90 0.84 1.11 0.73 0.68 0.76 0.49 0.76 0.84 1.00 0.96 0.96 1.17 1.12 0.93 0.81 1.35 1.15 1.01 1.00 0.52 0.36 0 82 1.30 Med 1.00 0.98 0.91 0.87 1.16 0.60 0.76 0.84 1.00 0.96 0.96 1.17 1.12 0.93 0.81 1.35 1.15 1.01 1.00 0.52 0.36 0 82 1.30 Med 1.00 0.98 0.91 0.98 0.91 0.98 0.97 1.23 1.18 0.95 0.84 1.51 1.37 1.04 1.00 0.68 0.80 1.25	Med	0.99	0.99	0.90	0.87	1.18	0.87	0.78	0.79	0.99	0.69	0.60	0.79	0.98	1.00	0.98	0.98	0.93	1.26	1.18	0.95	0.78	1.44	1.39	1.04	1.00	0.67	0.80	1	105	168
Transport Transport 5% 1.00 0.98 0.90 0.84 1.11 0.73 0.68 0.76 1.00 0.57 0.49 0.76 0.84 1.00 0.96 0.96 0.17 1.12 0.93 0.81 1.35 1.15 1.01 1.00 0.52 0.36 0 82 1.30 Med 1.00 0.98 0.91 0.87 1.16 0.80 0.80 0.80 0.65 0.60 0.79 0.84 1.01 0.86 0.87 0.84 1.01 0.98 0.97 1.23 1.18 0.95 0.84 1.51 1.37 1.04 1.00 0.68 0.80 1 1.07 1.01 1.00 0.68 0.80 1 1.07 1.01 1.00 0.68 0.80 1.01 1.00 0.81 1.03 1.01 1.00 0.81 0.83 1.25 0.23 1.04 0.98 0.87 1.21 0.81 0.81 0.81 0.83 1.25 0.23 1.01 0.98 0.81	95%	1.00	0.99	0.91	0.89	1.33	0.91	0.87	0.83	1.00	0.75	0.75	0.83	1.00	1.23	1.19	1.06	0.94	1.31	1.21	0.98	0.83	1.55	1.63	1.07	1.00	0.82	0.88	3	125	204
5% 1.00 0.58 0.90 0.84 1.11 0.75 0.68 0.76 0.49 0.76 0.84 1.00 0.96 0.96 1.17 1.12 0.95 0.81 1.35 1.15 1.01 1.00 0.52 0.36 0 82 130 Med 1.00 0.98 0.91 0.87 1.16 0.80 0.78 0.80 1.00 0.65 0.60 0.79 0.98 1.01 0.95 0.84 1.51 1.37 1.04 1.00 0.68 0.80 1 1.07 1.11 95% 1.00 0.98 0.91 0.89 0.19 0.86 0.87 0.83 1.00 0.75 0.83 1.00 1.39 1.23 1.06 0.98 1.29 1.21 0.98 0.87 1.72 1.61 1.07 1.00 0.88 3 125 203 Trial 6b0 5% 1.02 0.98 0.50 0.75 0.52 1.00 0.96 0.96 0.82 1.15 1.17 1.16 1.01 1.00	I rial 5a	1.00	0.00	0.00	0.04		0.72	0.69	0.76	1.00	0.57	0.40	0.76	0.94	1.00	0.00	0.07	0.07	1.17	1.12	0.02	0.01	1.25	1.16	1.01	1.00	0.52	0.26	0	00	120
Neta 1.00 0.58 0.91 0.87 1.16 0.80 0.78 0.60 1.00 0.53 0.64 1.51 1.51 1.51 1.64 1.00 0.86 0.80 1 107 111 95% 1.00 0.98 0.91 0.89 1.19 0.86 0.87 0.83 1.00 0.75 0.83 1.00 1.39 1.23 1.16 0.98 0.87 1.72 1.61 1.07 1.00 0.88 3 125 203 Trial 6b0 5% 1.02 0.98 0.50 0.75 0.52 1.00 0.96 0.82 1.05 1.12 0.93 0.37 1.07 1.16 1.01 1.00 0.55 0.40 0 85 138 5% 1.02 0.98 0.96 0.82 1.05 1.12 0.93 0.37 1.07 1.16 1.01 1.00 0.55 0.40 0 85 138	5% Mad	1.00	0.98	0.90	0.84	1.11	0.75	0.08	0.76	1.00	0.57	0.49	0.70	0.84	1.00	0.96	0.96	0.96	1.17	1.12	0.95	0.81	1.55	1.15	1.01	1.00	0.52	0.36	1	107	150
50% 1.00 0.58 0.51 0.69 0.63 1.00 0.74 0.75 0.63 1.00 1.35 1.23 1.00 0.56 0.61 1.00 0.61 0.68 3 1.23 2.05 Trial 6b0 5% 1.02 0.98 0.96 0.82 1.05 1.12 0.93 0.37 1.07 1.16 1.01 1.00 0.55 0.40 0 85 138	05%	1.00	0.98	0.91	0.87	1.10	0.86	0.78	0.80	1.00	0.05	0.00	0.79	1.00	1.01	1.22	1.06	0.97	1.25	1.10	0.95	0.87	1.51	1.57	1.04	1.00	0.03	0.80	2	107	202
5% 1.02 0.98 0.90 0.83 1.11 0.95 0.69 0.76 1.02 0.89 0.50 0.75 0.52 1.00 0.96 0.96 0.82 1.05 1.12 0.93 0.37 1.07 1.16 1.01 1.00 0.55 0.40 0 85 138	Trial 6b	1.00	0.98	0.91	0.89	1.19	0.80	0.87	0.85	1.00	0.74	0.75	0.85	1.00	1.59	1.23	1.00	0.98	1.29	1.21	0.98	0.87	1.72	1.01	1.07	1.00	0.81	0.88	5	125	205
	5%	,	0.98	0.90	0.83	1.11	0.95	0.69	0.76	1.02	0.89	0.50	0.75	0.52	1.00	0.96	0.96	0.82	1.05	1.12	0.93	0.37	1.07	1.16	1.01	1.00	0.55	0.40	0	85	138
Med 120 0.99 0.90 0.86 2.19 0.97 0.78 0.79 1.20 0.91 0.61 0.79 0.88 1.00 0.98 0.98 0.82 1.06 1.18 0.95 0.46 1.08 1.37 1.03 1.00 0.69 0.80 1 1.09 1.72	Med	1.02	0.99	0.90	0.86	2.19	0.97	0.78	0.79	1.02	0.91	0.61	0.79	0.52	1.00	0.98	0.98	0.82	1.05	1.12	0.95	0.46	1.08	1.10	1.03	1.00	0.69	0.40	1	109	150
95% 1.28 0.99 0.91 0.88 2.75 0.97 0.87 0.83 1.28 0.92 0.74 0.83 1.00 1.04 1.23 1.06 0.92 1.07 1.21 0.98 0.85 1.10 1.58 1.06 1.00 0.82 0.88 3 1.25 204	95%	1.28	0.99	0.91	0.88	2.75	0.97	0.87	0.83	1.28	0.92	0.74	0.83	1.00	1.04	1.23	1.06	0.92	1.07	1.21	0.98	0.85	1.10	1.58	1.05	1.00	0.82	0.88	3	125	204

		D1 (1+)	(10)			D1 (1+)	(100)			D2 (1+)	(100)			D8 (1+)	(100)			D10 (1+) (10)			D10 (1+	-) (100)		N9(N)	N(P)	N9(P)	WG	UL	US
	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	100	100	10	100	100	100
Trial 3a0																														
5%	1.00	0.99	0.90	0.83	1.00	0.90	0.69	0.75	0.98	0.75	0.50	0.75	1.00	1.00	0.96	0.96	1.00	1.13	1.12	0.93	1.00	1.19	1.17	1.01	1.00	0.54	0.36	0	86	134
Med	1.00	0.99	0.91	0.87	1.00	0.93	0.78	0.79	0.98	0.81	0.60	0.79	1.00	1.00	0.98	0.97	1.01	1.14	1.18	0.95	1.02	1.22	1.39	1.04	1.00	0.68	0.80	1	105	171
95%	1.00	0.99	0.91	0.89	1.00	0.94	0.86	0.83	1.00	0.83	0.73	0.83	1.01	1.10	1.21	1.06	1.01	1.19	1.21	0.98	1.02	1.31	1.60	1.07	1.00	0.82	0.88	3	127	204
Trial 3a1																														
5%	1.00	0.99	0.63	0.72	1.00	0.90	0.69	0.75	0.98	0.75	0.43	0.72	1.00	1.00	0.83	0.91	1.00	1.13	1.12	0.93	1.00	1.19	1.06	0.89	1.00	0.43	0.32	0	63	108
Med	1.00	0.99	0.73	0.77	1.00	0.93	0.78	0.79	0.98	0.81	0.54	0.77	1.00	1.00	1.00	0.95	1.01	1.14	1.18	0.95	1.02	1.22	1.11	0.93	1.00	0.65	0.80	1	101	163
95%	1.00	0.99	0.82	0.81	1.00	0.94	0.86	0.83	1.00	0.83	0.64	0.81	1.01	1.10	1.31	0.98	1.01	1.19	1.21	0.98	1.02	1.31	1.17	0.95	1.00	0.77	0.88	3	121	192
Trial 3a2																														
5%	1.00	0.99	0.89	0.83	1.00	0.90	0.69	0.73	0.98	0.75	0.50	0.72	1.00	1.00	0.96	0.96	1.00	1.13	1.12	0.95	1.00	1.19	1.15	1.03	1.00	0.54	0.36	0	83	134
Med	1.00	0.99	0.90	0.87	1.00	0.93	0.78	0.78	0.98	0.82	0.61	0.77	1.00	1.00	0.98	0.98	1.01	1.14	1.18	0.99	1.02	1.22	1.36	1.10	1.00	0.69	0.80	1	106	172
95%	1.00	0.99	0.91	0.89	1.00	0.94	0.87	0.82	1.00	0.84	0.75	0.82	1.01	1.10	1.20	1.10	1.01	1.20	1.21	1.04	1.02	1.32	1.58	1.18	1.00	0.82	0.88	3	127	204
Trial 3a3																														
5%	1.00	0.99	0.89	0.75	1.00	0.90	0.69	0.68	0.98	0.75	0.50	0.58	1.00	1.00	0.96	0.89	1.00	1.13	1.12	0.89	1.00	1.18	1.15	0.98	1.00	0.50	0.32	0	78	126
Med	1.00	0.99	0.90	0.83	1.00	0.93	0.78	0.77	0.98	0.82	0.61	0.72	1.00	1.00	0.98	0.97	1.01	1.14	1.18	0.97	1.02	1.22	1.36	1.05	1.00	0.65	0.80	1	101	162
95%	1.00	0.99	0.91	0.87	1.00	0.94	0.87	0.81	1.00	0.84	0.75	0.81	1.01	1.10	1.20	1.09	1.01	1.20	1.21	1.03	1.02	1.32	1.58	1.12	1.00	0.81	0.88	3	124	202
Trial 3a4																														
5%	1.00	0.99	0.64	0.67	1.00	0.90	0.69	0.65	0.98	0.75	0.45	0.58	1.00	1.00	0.82	0.88	1.00	1.13	1.12	0.87	1.00	1.19	1.05	0.88	1.00	0.30	0.32	0	47	75
Med	1.00	0.99	0.74	0.75	1.00	0.93	0.78	0.77	0.98	0.82	0.55	0.68	1.00	1.00	1.00	0.95	1.01	1.14	1.18	0.96	1.02	1.22	1.11	0.94	1.00	0.56	0.80	1	91	141
95%	1.00	0.99	0.82	0.80	1.00	0.94	0.87	0.82	1.00	0.84	0.65	0.78	1.01	1.10	1.31	1.06	1.01	1.20	1.21	1.04	1.02	1.32	1.16	1.04	1.00	0.74	0.88	3	116	185

Table 5. Performance statistics for the trials 3a0 and 3a2 and variants thereof in which there are future mortality events.

		D1 (1+)	(10)			D1 (1+)	(100)			D2 (1+)	(100)			D8 (1+)	(100)			D10 (1+) (10)			D10 (1-	+) (100)		N9(N)	N(P)	N9(P)	WG	UL	US
	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	WB	WF	NF	PC	100	100	10	100	100	100
Trial 5a0																														
5%	1.00	0.98	0.90	0.84	1.11	0.73	0.68	0.76	1.00	0.57	0.49	0.76	0.84	1.00	0.96	0.96	0.96	1.17	1.12	0.93	0.81	1.35	1.15	1.01	1.00	0.52	0.36	0	82	130
Med	1.00	0.98	0.91	0.87	1.16	0.80	0.78	0.80	1.00	0.65	0.60	0.79	0.98	1.01	0.98	0.98	0.97	1.23	1.18	0.95	0.84	1.51	1.37	1.04	1.00	0.68	0.80	1	107	171
95%	1.00	0.98	0.91	0.89	1.19	0.86	0.87	0.83	1.00	0.74	0.75	0.83	1.00	1.39	1.23	1.06	0.98	1.29	1.21	0.98	0.87	1.72	1.61	1.07	1.00	0.81	0.88	3	125	203
Trial 5a1																														
5%	1.00	0.98	0.63	0.73	1.11	0.73	0.68	0.76	1.00	0.57	0.43	0.72	0.84	1.00	0.82	0.92	0.96	1.17	1.12	0.93	0.81	1.35	1.05	0.90	1.00	0.37	0.32	0	56	93
Med	1.00	0.98	0.74	0.78	1.16	0.80	0.78	0.80	1.00	0.65	0.54	0.77	0.98	1.01	1.00	0.95	0.97	1.23	1.18	0.95	0.84	1.51	1.11	0.93	1.00	0.65	0.80	1	102	163
95%	1.00	0.98	0.83	0.83	1.19	0.86	0.87	0.84	1.00	0.74	0.66	0.82	1.00	1.39	1.32	0.98	0.98	1.29	1.21	0.98	0.87	1.72	1.17	0.97	1.00	0.81	0.88	2	126	202
Trial 5a2																														
5%	0.99	0.98	0.89	0.84	1.14	0.74	0.69	0.74	0.99	0.56	0.50	0.72	0.83	1.00	0.96	0.96	0.96	1.19	1.12	0.95	0.78	1.38	1.15	1.03	1.00	0.54	0.36	0	82	134
Med	1.00	0.98	0.90	0.87	1.17	0.79	0.78	0.78	1.00	0.63	0.61	0.77	0.98	1.01	0.98	0.98	0.96	1.25	1.18	0.99	0.82	1.57	1.36	1.10	1.00	0.67	0.80	1	106	169
95%	1.00	0.99	0.91	0.89	1.22	0.85	0.87	0.82	1.00	0.72	0.75	0.82	1.00	1.42	1.21	1.10	0.97	1.31	1.21	1.04	0.84	1.74	1.59	1.19	1.00	0.82	0.88	3	124	205
Trial 5a3																														
5%	0.99	0.98	0.89	0.72	1.14	0.74	0.69	0.65	0.99	0.56	0.50	0.60	0.83	1.00	0.96	0.89	0.96	1.19	1.12	0.89	0.78	1.38	1.15	0.98	1.00	0.47	0.32	0	78	117
Med	1.00	0.98	0.90	0.83	1.17	0.79	0.78	0.77	1.00	0.63	0.61	0.71	0.98	1.01	0.98	0.97	0.96	1.25	1.18	0.97	0.82	1.57	1.36	1.05	1.00	0.64	0.80	1	101	161
95%	1.00	0.99	0.91	0.87	1.22	0.85	0.87	0.82	1.00	0.72	0.75	0.80	1.00	1.42	1.21	1.10	0.97	1.31	1.21	1.04	0.84	1.74	1.59	1.11	1.00	0.80	0.88	3	123	201
Trial 5A	Ļ																													
5%	0.99	0.98	0.64	0.65	1.14	0.74	0.69	0.66	0.99	0.56	0.44	0.56	0.83	1.00	0.83	0.88	0.96	1.19	1.12	0.87	0.78	1.38	1.05	0.87	1.00	0.26	0.32	0	40	65
Med	1.00	0.98	0.74	0.75	1.17	0.79	0.78	0.77	1.00	0.63	0.55	0.68	0.98	1.01	1.00	0.95	0.96	1.25	1.18	0.97	0.82	1.57	1.11	0.94	1.00	0.57	0.80	1	90	142
95%	1.00	0.99	0.83	0.80	1.22	0.85	0.87	0.82	1.00	0.72	0.66	0.79	1.00	1.42	1.32	1.06	0.97	1.31	1.21	1.04	0.84	1.74	1.16	1.03	1.00	0.75	0.88	3	115	188

Table 6. Performance statistics for the trials 5a0 and 5a2 and variants thereof in which there are future mortality events.





Figure 1. The sub-areas in the operating model (IWC, 2019a). OS = Okhotsk Sea, SI = Sakhalin Island, SKNK =

301 Southern Kamchatka and Northern Kuril Islands, BSCS = Northern Bering and Chukchi Sea, SEA = Southeast Alaska;

BCNC = British Columbia to Northern California, KWJ = Korea and the west coast of Japan, EJPJ = east coast of

Japan, CA = California, VSC = Vietnam-South China Sea, M = Mexico. Colors indicate: breeding (orange), migration
 (green), and feeding (blue) grounds.

305



307 308 309 Figure 2. Abundance for California (upper panel) and the PCFG (lower panel). The values used in the Gray Whale Rangewide Review are indicted by lines and new estimates are indicated by dots.



Figure 3. Fits to the abundance estimates for the base-case trials (3a0 and 5a0) and variants thereof that estimate a
 mortality event for the PCFG in 2016 (3a2 and 5a2). WST denotes the Western Breeding Stock.





315 316 Figure 4. Fits to the abundance estimates for the six trials that explore sensitivity to stock structure uncertainty (3a0, 317 3b0, 3c0, 3e0, 5a0, and 6b0). None of the models allow for a mortality event in the PCFG.



Figure 5. Fits to the mixing proportions (first column), the assumed immigration rate of 2 (second column), the average bycatches (third column), and the PCFG survival rates (fourth column) for the base-case trials (3a0 and 5a0) and

variants thereof that estimate a mortality event for the PCFG in 2026 (3a2 and 5a2).





Figure 6. Fits to the mixing proportions (first column), the assumed immigration rate of 2 (second column), the average

- by catches (third column), and the PCFG survival rates (fourth column) for the six trials that explore sensitivity to
- stock structure uncertainty (3a0, 3b0, 3c0, 3e0, 5a0, and 6b0).



Figure 7(a). Distribution of estimates of (key) parameters for trial 3a0. Note that the mortality rate for the PCFG is not
 estimated (set to 1), and the additional CVs for the California counts and the PCFG estimates are set to 0.15 and 0.005

- respectively. "mat fem K" denotes the number of mature females in the unexploited state while "Init Depl" is the ratioof the 1930 population size to carrying capacity.
- 334



Figure 7(b). Distribution of estimates of (key) parameters for trial 3a2. Note that additional CVs for the California

- 337 counts and the PCFG estimates are set to 0.15 and 0.005 respectively. "mat fem K" denotes the number of mature
- females in the unexploited state while "Init Depl" is the ratio of the 1930 population size to carrying capacity.
- 339





Figure 9. Four example time-trajectories of 1+ numbers for the NFG and PCFG for trials 3a0, 3a1, 3a2, 3a3, and 3a4.
The projection allows for aboriginal catches in the Russian hunt but no future Makah hunt.

Appendix A The Makah Management Plan (source: IWC, 2019a, pg 598) The Makah Management Plan (source: IWC, 2019a, pg 598)

Proposed Makah Management Plan





